Strategies for improving DNA vaccine performance

Methods in Molecular Biology

Volumn 1143, Issue , 2014, Pages 21-31

  Iurescia, Sandra ^a   Fioretti, Daniela ^a   Rinaldi, Monica ^a  

^a NONE

Author keywords

Adaptive immunity; Antigen targeting; Antigen epitope optimization; DNA vaccines; Genetic adjuvants; Innate immunity; T cell help; Targeting sequences

Indexed keywords

DNA VACCINE; ANTIGEN; EPITOPE;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; DNA IMMUNIZATION; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; PRIORITY JOURNAL; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HUMANS; IMMUNITY, INNATE; VACCINES, DNA;

EID: 84907682258     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0410-5_3     Document Type: Article

References (62)

1. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9: 776–788
2. Scarselli E, Mennuni C, La Monica N et al. (2011) Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof. US8017387
3. Smahel M, Sima P, Ludvikova V et al (2001) Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281:231–238
4. Cassetti MC, McElhiney SP, Shahabi V et al (2004) Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22:520–527
5. Osen W, Peiler T, Ohlschlager P et al (2001) A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19: 4276–4286
6. Ohlschlager P, Pes M, Osen W et al (2006) An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wild type-specific T cell response. Vaccine 24:2880–2893
7. Oosterhuis K, Ohlschlager P, van den Berg JH et al (2011) Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E 7. Int J Cancer 129:397–406
8. Dormitzer PR, Ulmer JB, Rappuoli R (2008) Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol 26:659–667
9. Dormitzer PR, Grandi G, Rappuoli R (2012) Structural vaccinology starts to deliver. Nat Rev Microbiol 10:807–813
10. Kim Y, Sette A, Peters B (2011) Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. J Immunol Methods 374:62–69
11. Rosa DS, Ribeiro SP, Cunha-Neto E (2010) CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp (Warsz) 58:121–130
12. Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178–228
13. Sette A, Buus S, Appella E et al (1989) Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A 86:3296–3300
14. Iurescia S, Fioretti D, Fazio VM et al (2012) Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech’s challenge. Biotechnol Adv 30:372–383
15. Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1: 209–219
16. Borbulevych OY, Baxter TK, Yu Z et al (2005) Increased immunogenicity of an anchormodified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol 174:4812–4820
17. Slansky JE, Rattis FM, Boyd LF et al (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529–538
18. Buhrman JD, Slansky JE (2013) Improving T cell responses to modified peptides in tumor vaccines. Immunol Res 55:34–47
19. Stevenson FK, Rice J, Ottensmeier CH et al (2004) DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 199:156–180
20. Zinkernagel RM (2002) Uncertainties: discrepancies in immunology. Immunol Rev 185: 103–125
21. Janssen EM, Lemmens EE, Wolfe T et al (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852–856
22. Panina-Bordignon P, Tan A, Termijtelen A et al (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19:2237–2242
23. Egan AF, Blackman MJ, Kaslow DC (2000) Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun 68:1418–1427
24. Lee EA, Palmer DR, Flanagan KL et al (2002) Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 70:1417–1421
25. Valmori D, Fonteneau JF, Lizana CM et al (1998) Enhanced generation of specific tumorreactive CTL in vitro by selected Melan-A/ MART-1 immunodominant peptide analogues. J Immunol 160:1750–1758
26. Iurescia S, Fioretti D, Pierimarchi P et al (2010) Genetic immunization with CDR3- based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma. J Biomed Biotechnol 2010:316069
27. Lund LH, Andersson K, Zuber B et al (2003) Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 10:365–376
28. Rice J, Elliott T, Buchan S et al (2001) DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 167:1558–1565
29. Iurescia S, Fioretti D, Fazio VM et al (2011) Design and pre-clinical development of epitope- based DNA vaccines against B-cell lymphoma. Curr Gene Ther 11:414–422
30. Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108–120
31. Chaise C, Buchan SL, Rice J et al (2008) DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 112:2956–2964
32. Signori E, Iurescia S, Massi E et al (2010) DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 59:1583–1591
33. Demotz S, Barbey C, Corradin G et al (1993) The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 23: 425–432
34. James EA, Bui J, Berger D et al (2007) Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLAbased differences in epitope recognition. Int Immunol 19:1291–1301
35. Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51–88
36. Chen W, McCluskey J (2006) Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cellbased cancer vaccines. Adv Cancer Res 95:203–247
37. Fioretti D, Iurescia S, Rinaldi M (2013) Recent advances in design of immunogenic and effective naked DNA vaccines against cancer. Recent Pat Anticancer Drug Discov 9:66–82
38. Wang G, Pan L, Zhang Y (2011) Approaches to improved targeting of DNA vaccines. Hum Vaccin 7:1271–1281
39. Jensen PE (2007) Recent advances in antigen processing and presentation. Nat Immunol 8:1041–1048
40. Yewdell JW, Bennink JR (2001) Cut and trim: generating MHC class I peptide ligands. Curr Opin Immunol 13:13–18
41. Leifert JA, Rodriguez-Carreno MP, Rodriguez F et al (2004) Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol Rev 199:40–53
42. Cheng WF, Hung CF, Chai CY et al (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669–678
43. Lin CT, Chang TC, Chao A et al (2005) Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. J Biomed Sci 12:279–287
44. Bins AD, Wolkers MC, van den Boom MD et al (2007) In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 179:2126–2133
45. Oosterhuis K, Aleyd E, Vrijland K et al (2012) Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther 23:1301–1312
46. Ji H, Wang TL, Chen CH et al (1999) Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 10:2727–2740
47. Delogu G, Li A, Repique C et al (2002) DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 70:292–302
48. Norbury CC, Princiotta MF, Bacik I et al (2001) Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol 166:4355–4362
49. Watts C (1997) Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15:821–850
50. Wang S, Hackett A, Jia N et al (2011) Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 6:e28757
51. Wang JY, Song WT, Li Y et al (2011) Improved expression of secretory and trimeric proteins in mammalian cells via the introduction of a new trimer motif and a mutant of the tPA signal sequence. Appl Microbiol Biotechnol 91:731–740
52. Hung CF, Cheng WF, Hsu KF et al (2001) Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698–3703
53. Mohammed AF, Abdul-Wahid A, Huang EH et al (2012) The Pseudomonas aeruginosa exotoxin A translocation domain facilitates the routing of CPP-protein cargos to the cytosol of eukaryotic cells. J Control Release 164:58–64
54. Carvalho JA, Azzoni AR, Prazeres DM et al (2010) Comparative analysis of antigentargeting sequences used in DNA vaccines. Mol Biotechnol 44:204–212
55. Li L, Saade F, Petrovsky N (2012) The future of human DNA vaccines. J Biotechnol 162:171–182
56. Fioretti D, Iurescia S, Fazio VM et al (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378. doi: 10.1155/2010/174378
57. Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11:189–209
58. Tovey MG, Lallemand C (2010) Adjuvant activity of cytokines. Methods Mol Biol 626:287–309
59. Anderson RJ, Schneider J (2007) Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25(Suppl 2):B24–B34
60. Cuddapah S, Barski A, Zhao K (2010) Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol 22:341–347
61. Kennedy RB, Poland GA (2011) The top five “game changers” in vaccinology: toward rational and directed vaccine development. OMICS 15:533–537
62. Moss RB (2009) Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Immune Based Ther Vaccines 7:3